Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 18;2(5):e001007.
doi: 10.1136/bmjopen-2012-001007. Print 2012.

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

Christine Clar  1 , James Alexander Gill, Rachel Court, Norman Waugh
Affiliations

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

Christine Clar et al. BMJ Open. .

Abstract

Background: Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends to be a progressive disease, and most patients require treatment with combinations of glucose-lowering agents. The sodium glucose co-transporter 2 (SGLT2) receptor inhibitors are a new class of glucose-lowering agents.

Objective: To assess the clinical effectiveness and safety of the SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Data sources: MEDLINE, Embase, Cochrane Library (all sections); Science Citation Index; trial registries; conference abstracts; drug regulatory authorities; bibliographies of retrieved papers.

Inclusion criteria: Randomised controlled trials of SGLT2 receptor inhibitors compared with placebo or active comparator in type 2 diabetes in dual or combination therapy.

Methods: Systematic review. Quality assessment used the Cochrane risk of bias score.

Results: Seven trials, published in full, assessed dapagliflozin and one assessed canagliflozin. Trial quality appeared good. Dapagliflozin 10 mg reduced HbA1c by -0.54% (weighted mean differences (WMD), 95% CI -0.67 to -0.40) compared to placebo, but there was no difference compared to glipizide. Canagliflozin reduced HbA1c slightly more than sitagliptin (up to -0.21% vs sitagliptin). Both dapagliflozin and canagliflozin led to weight loss (dapagliflozin WMD -1.81 kg (95% CI -2.04 to -1.57), canagliflozin up to -2.3 kg compared to placebo).

Limitations: Long-term trial extensions suggested that effects were maintained over time. Data on canagliflozin are currently available from only one paper. Costs of the drugs are not known so cost-effectiveness cannot be assessed. More data on safety are needed, with the Food and Drug Administration having concerns about breast and bladder cancers.

Conclusions: Dapagliflozin appears effective in reducing HbA1c and weight in type 2 diabetes, although more safety data are needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Search results.
Figure 2
Figure 2
Meta-analysis for HbA1c change from baseline, 10 mg dapagliflozin versus placebo.
Figure 3
Figure 3
HbA1c change in response to canagliflozin (Rosenstock et al, means and SE).
Figure 4
Figure 4
Meta-analysis for weight change from baseline, 10 mg dapagliflozin versus placebo.
See this image and copyright information in PMC

References

    1. Diabetes UK. Diabetes in the UK: key statistics on diabetes. http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf 2010. (accessed 2 Aug 2012).
    1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76–9 - PubMed
    1. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49–57 - PubMed
    1. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873–82 - PubMed
    1. Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196–8 - PubMed

LinkOut - more resources